New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
07:25 EDTJAZZ, AGN, VRX, ALKS, SHPGAllergan approached Shire about potential takeover months ago, Reuters says
Allergan (AGN) reportedly approached Shire (SHPG) several months ago about a possible takeover, Reuters reports, though initial conversations never turned into more serious discussions. Since then, Allergan has received an unsolicited $47B offer from Valeant (VRX) and Pershing Square. It is unclear whether Allergan will look to revive talks with Shire or pursue another acquisition target like Jazz (JAZZ) or Alkermes (ALKS). Reference Link
News For AGN;SHPG;VRX;JAZZ;ALKS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
17:22 EDTAGNAllergan reports 6.7% stake in KYTHERA
07:10 EDTJAZZJazz Pharmaceuticals price target raised to $210 from $190 at UBS
UBS raised its price target on Jazz Pharmaceuticals to $210 from $190 on expectations for Xyrem sales growth, its lower tax rate and its strong balance sheet. UBS reiterated its Buy rating on Jazz Pharmaceuticals shares.
June 26, 2015
16:16 EDTVRXOn The Fly: Top stock stories for Friday
Subscribe for More Information
09:37 EDTVRXValeant unlikely to pursue Zoetis acquisition, CNBC's Faber says
Subscribe for More Information
09:33 EDTVRXValeant made Zoetis approach as courtesy to Ackman, CNBC reports
Subscribe for More Information
09:33 EDTVRXValeant not going to pursue Zoetis acquisition, CNBC's Faber reports
07:52 EDTALKSAlkermes schizophrenia drug profile looks interesting, says Cowen
Subscribe for More Information
06:06 EDTVRXZoetis downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
06:02 EDTVRXJPMorgan assumes Valeant pays $60/share for Zoetis
JPMorgan analyst Chris Schott believes Zoetis (ZTS) would bring "an attractive, durable, cash-pay business" to Valeant's portfolio should a merger occur. The Wall Street Journal last night reported that Valeant has approached Zoetis regarding a potential takeover. Schott sees the deal being minimally accretive to near-term earnings, and assumes Valeant pays $60 per share for Zoetis, or a 20% premium to Wednesday's closing price. The analyst thinks any offer would include a substantial equity component given Valeant's levered balance sheet following the Salix acquisition. Schott keeps an Overweight rating on Valeant and a Neutral rating on Zoetis.
June 25, 2015
16:13 EDTVRXValeant made preliminary takeover approach to Zoetis, WSJ reports
Valeant Pharmaceuticals (VRX) made a preliminary approach regarding a potential deal to buy Zoetis (ZTS), said The Wall Street Journal, citing people familiar with the matter. The report said it was not clear if Zoetis is open to a sale or what was the company’s reaction to the approach. Zoetis share spiked more than 11% into the close following the report and are up another 1% to $55.95 in after hours trading. Reference Link
15:58 EDTVRXZoetis jumps 11%, halted for circuit breaker after report of Valeant approach
Subscribe for More Information
15:57 EDTVRXValeant made preliminary takeover approach to Zoetis, DJ reports
Subscribe for More Information
13:58 EDTSHPGShire initiated with a Reduce at HSBC
Price target GBP 47.34.
08:13 EDTAGNAllergan CEO: Irvine campus ‘crucial’ to company, L.A. Times reports
New Allergan CEO Brent Saunders said that the company’s Irvine, California campus is “crucial” to the recently purchased organization, the L.A. Times reports, citing comments from Saunders in an interview. Allergan was purchased in March by Actavis, a move which led to the layoff of roughly 600 employees from the Irvine offices, the report says. Saunders said that the “bleeding has stopped” after a round of layoffs, the L.A. Times says. Reference Link
June 24, 2015
07:48 EDTALKSAlkermes data support ALKS 3831 potential, says Credit Suisse
Subscribe for More Information
05:51 EDTALKSAlkermes physician call on ALKS 3831 encouraging, says UBS
Subscribe for More Information
June 23, 2015
09:20 EDTVRXValeant and Progenics announces submission of NDA to FDA for RELISTOR
Valeant Pharmaceuticals International (VRX) and Progenics Pharmaceuticals (PGNX) announced that Valeant submitted a New Drug Application, or NDA, to the FDA for RELISTOR, or methylnaltrexone bromide, Tablets for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
07:25 EDTVRXPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 19, 2015
16:24 EDTAGNStocks end week higher after Fed reassures on gradual pace of rate increases
Subscribe for More Information
10:31 EDTALKSAlkermes to host conference call
Conference call to discuss the six-month data of ALKS 3831 for the treatment of schizophrenia will be held on June 23 at 8 am. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use